Resources Repository
-
DataWeb Portal 2024OECD Health Statistics
The Organisation for Economic Co-operation and Development (OECD) Health Database offers a comprehensive source of …
The Organisation for Economic Co-operation and Development (OECD) Health Database offers a comprehensive source of comparable statistics on health and health systems across OECD countries. These data serve to facilitate and support comparative analyses, and can be useful for researchers, educators and policy makers looking to draw lessons from international comparisons of diverse health systems. General categories of data include population demographics, health status and determinants of health, as well as data on the societal responses to health…
Europe | Latin America & Caribbean | North America | Health Outcomes | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Education/Labor | Health/Medicine | Science/Technology | Oceania -
ReviewPublication 2017Patients' Preferences in Cancer Treatment: Review of Discrete Choice Experiments
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer …
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer treatment and assessed the relative importance of outcome, process and cost attributes. A systematic literature review was conducted using PubMed and EMBASE to identify all DCEs investigating patients’ preferences for cancer treatment between January 2010 and April 2016. Attributes were classified into outcome, process and cost attributes, and their relative importance was assessed. A total of 28 DCEs were identified.…
Europe | North America | Preferences/Values | Health Outcomes | Decision Analysis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine -
ReviewPublication 2015Economic Evaluation of Diet and Physical Activity to Prevent Type 2 Diabetes: Systematic Review
Studies indicate that combined diet and physical activity promotion programs can prevent type 2 diabetes …
Studies indicate that combined diet and physical activity promotion programs can prevent type 2 diabetes among persons at increased risk. This paper systematically evaluates the evidence on cost, cost-effectiveness, and cost–benefit estimates of diet and physical activity promotion programs. English-language studies from high-income countries that provided data on cost, cost-effectiveness, or cost–benefit ratios of diet and physical activity promotion programs with at least 2 sessions over at least 3 months delivered to persons at increased risk…
Europe | North America | Evidence Synthesis | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Social Determinants | Health Systems | Food/Agriculture | Health/Medicine | Asia & Pacific -
ReviewPublication 2015Population Health: Behavioral and Social Science Insights
This book comprises 23 chapters focused on what the effects of various behavioral and social factors …
This book comprises 23 chapters focused on what the effects of various behavioral and social factors on longevity, disability and illness, and quality of life, primarily at the population level. Factors such as access to health care, educational attainment, nutrition, physical activity, use of tobacco products, and non-communicable diseases are considered, along with many other determinants of health and longevity. Of particular interest for health decision scientists are the following chapters: In Section 4: The Science…
Europe | North America | Priority Setting/Ethics | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health/Medicine | Global -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
North America | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine -
ReviewPublication 2021Considerations for Diagnostic COVID-19 Tests
During the initial stages of the COVID-19 pandemic, there was a rush by numerous diagnostic …
During the initial stages of the COVID-19 pandemic, there was a rush by numerous diagnostic test manufacturers to create, validate, and implement testing methods. This review discusses the pivotal role of diagnostic tests during the pandemic's first global wave, highlighting the challenges in technology and implementation experienced early on. The study also offers insights for enhancing the use of diagnostics, especially syndromic ones, should there be future spikes or regional outbreaks of COVID-19. The overarching…
North America | Test Performance | Infectious Diseases | Clinical Care | Health/Medicine | Science/Technology -
ReviewPublication 2022Rapid, Point-of-Care Antigen Tests for Diagnosis of SARS-CoV-2 Infection
This study reviewed the diagnostic accuracy of rapid, point-of-care antigen tests for detecting SARS-CoV-2 infection, …
This study reviewed the diagnostic accuracy of rapid, point-of-care antigen tests for detecting SARS-CoV-2 infection, differentiating results between symptomatic and asymptomatic individuals. Using data from 155 study cohorts, the study found that the sensitivity of antigen tests was generally higher for symptomatic individuals, especially during the first week after symptom onset, due to higher viral loads. For example, average sensitivity was higher in symptomatic (73.0%) compared to asymptomatic participants (54.7). Average sensitivity was higher in…
North America | Test Performance | Infectious Diseases | Clinical Care | Health/Medicine | Science/Technology -
ReviewPublication 2022Significance of Advanced COVID-19 Diagnostic Testing in Pandemic Control Measures
Over the past two years of the COVID-19 pandemic, the scientific community has mounted significant …
Over the past two years of the COVID-19 pandemic, the scientific community has mounted significant efforts to combat the highly transmissible SARS-CoV-2 virus. Despite substantial progress in vaccines and treatments, leading to lower hospitalization and death rates, the virus has continued to evolve, primarily through mutations. From the onset, diagnostic tests have been crucial in identifying and controlling the virus spread. The scientific world has pioneered various diagnostic techniques, including nucleic acid, antigen, and antibody-based…
North America | Test Performance | Infectious Diseases | Health Systems | Clinical Care | Health/Medicine | Science/Technology -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
North America | Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Social Determinants | Culture/Society | Economics/Finance | Health/Medicine